Literature DB >> 25148608

Preparation and evaluation of polyamidoamine dendrimer conjugate with glucuronylglucosyl-β-cyclodextrin (G3) as a novel carrier for siRNA.

Ahmed Fouad Abdelwahab1, Ayumu Ohyama, Taishi Higashi, Keiichi Motoyama, Khaled Ali Khaled, Hatem Abdelmonsef Sarhan, Amal Kamal Hussein, Hidetoshi Arima.   

Abstract

Abstract In this study, we newly synthesized the polyamidoamine STARBURST dendrimer (dendrimer, generation 3: G3) conjugates with 6-O-α-(4-O-α-D-glucuronyl)-D-glucosyl-β-cyclodextrin [GUG-β-CDE (G3)] having the various degrees of substitution (DS) of GUG-β-cyclodextrin of 1.6, 3.0, 3.7, 5.0 and 8.6, and evaluated them as a siRNA transfer carrier. GUG-β-CDEs (G3) formed the positively charged and nano-order complexes with siRNA. Of the siRNA complexes with five GUG-β-CDEs (G3), the complex with GUG-β-CDE (G3, DS 3.7) showed the highest RNAi effect and cellular uptake with negligible cytotoxicity in KB cells at a charge ratio of 20. In addition, the RNAi effect and cellular uptake of the complex with GUG-β-CDE (G3, DS 3.7) were higher than those of α-CDE (G3, DS 2.4) and comparable to those of Lipofectamine™ 2000. Furthermore, the complex with GUG-β-CDE (G3, DS 3.7) possessed the endosomal escaping ability, the releasing property of siRNA in the cytoplasm and serum resistance. These results suggest that GUG-β-CDE (G3, DS 3.7) has the potential as a novel siRNA carrier.

Entities:  

Keywords:  Conjugate; PAMAM dendrimer; glucuronylglucosyl-β-cyclodextrin; siRNA delivery

Mesh:

Substances:

Year:  2014        PMID: 25148608     DOI: 10.3109/1061186X.2014.950663

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  7 in total

Review 1.  Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery.

Authors:  Prashant Kesharwani; Arun K Iyer
Journal:  Drug Discov Today       Date:  2014-12-31       Impact factor: 7.851

2.  In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-β-Cyclodextrin Conjugate.

Authors:  Ahmed Fouad Abdelwahab Mohammed; Taishi Higashi; Keiichi Motoyama; Ayumu Ohyama; Risako Onodera; Khaled Ali Khaled; Hatem Abdelmonsef Sarhan; Amal Kamal Hussein; Hidetoshi Arima
Journal:  AAPS J       Date:  2019-04-16       Impact factor: 4.009

3.  A biocompatible poly(amidoamine) (PAMAM) dendrimer octa-substituted with α-cyclodextrin towards the controlled release of doxorubicin hydrochloride from its ferrocenyl prodrug.

Authors:  Artur Kasprzak; Bartłomiej Dabrowski; Agnieszka Zuchowska
Journal:  RSC Adv       Date:  2020-06-19       Impact factor: 4.036

4.  Efficient modification of PAMAM G1 dendrimer surface with β-cyclodextrin units by CuAAC: impact on the water solubility and cytotoxicity.

Authors:  Kendra Sorroza-Martínez; Israel González-Méndez; Ricardo D Martínez-Serrano; José D Solano; Andrea Ruiu; Javier Illescas; Xiao Xia Zhu; Ernesto Rivera
Journal:  RSC Adv       Date:  2020-07-07       Impact factor: 4.036

Review 5.  Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer.

Authors:  Shrey Kanvinde; Tanmay Kulkarni; Suyash Deodhar; Deep Bhattacharya; Aneesha Dasgupta
Journal:  BioTech (Basel)       Date:  2022-03-07

Review 6.  Twenty Years of Research on Cyclodextrin Conjugates with PAMAM Dendrimers.

Authors:  Hidetoshi Arima
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

7.  First Class of Phosphorus Dendritic Compounds Containing β-Cyclodextrin Units in the Periphery Prepared by CuAAC.

Authors:  Kendra Sorroza-Martínez; Israel González-Méndez; Mireille Vonlanthen; Kathleen I Moineau-Chane Ching; Anne-Marie Caminade; Javier Illescas; Ernesto Rivera
Journal:  Molecules       Date:  2020-09-04       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.